Inventor · disambiguated record
Lynnie Trzoss
Also filed as: TRZOSS LYNNIE · TRZOSS LYNNIE LIN
17 granted patents·9 pending applications·28 citations·filing 2015–2025
90Inventor score
Top patents by PatentIndex Score
26 records- 0196US11591331B2PARP1 inhibitors and uses thereofXINTHERA INC·Filed 2022·Granted Feb 28, 2023·6 cites·21 claims
- 0295US11680056B2MK2 inhibitors and uses thereofXINTHERA INC·Filed 2022·Granted Jun 20, 2023·3 cites·28 claims
- 0394US11802128B2Azetidine and pyrrolidine PARP1 inhibitors and uses thereofXINTHERA INC·Filed 2023·Granted Oct 31, 2023·3 cites·15 claims
- 0494US11685719B2Pyridinone MK2 inhibitors and uses thereofXINTHERA INC·Filed 2022·Granted Jun 27, 2023·3 cites·30 claims
- 0593US11939329B2PARP1 inhibitors and uses thereofXINTHERA INC·Filed 2023·Granted Mar 26, 2024·2 cites·5 claims
- 0691US11702428B2Chemical compounds as inhibitors of interleukin-1 activityGENENTECH INC·Filed 2022·Granted Jul 18, 2023·1 cites·24 claims
- 0789US11020380B2Therapeutic compoundsCELGENE QUANTICEL RES INC·Filed 2020·Granted Jun 1, 2021·2 cites·27 claims
- 0888US11890275B2Therapeutic compoundsCELGENE QUANTICEL RES INC·Filed 2021·Granted Feb 6, 2024·1 cites·44 claims
- 0988US11040985B2Chemical compounds as inhibitors of interleukin-1 activityGENENTECH INC·Filed 2019·Granted Jun 22, 2021·3 cites·74 claims
- 1085US10617680B2Therapeutic compoundsCELGENE QUANTICEL RES INC·Filed 2018·Granted Apr 14, 2020·3 cites·48 claims
- 1182US11987574B2MK2 inhibitors and uses thereofXINTHERA INC·Filed 2023·Granted May 21, 2024·0 cites·22 claims
- 1281US2024293381A1Therapeutic CompoundsCELGENE QUANTICEL RES INC·Filed 2024·Application pending·0 cites
- 1379US12384780B2PARP1 inhibitors and uses thereofXINTHERA INC·Filed 2024·Granted Aug 12, 2025·0 cites·2 claims
- 1477US12139462B2Pyridinone MK2 inhibitors and uses thereofXINTHERA INC·Filed 2023·Granted Nov 12, 2024·0 cites·30 claims
- 1575US2025115618A1Sulfonimidamide compounds as inhibitors of interleukin-1 activityGENENTECH INC·Filed 2024·Application pending·0 cites
- 1670US12410179B2Modulators of TNF alpha activity and uses thereofRAYTHERA INC·Filed 2024·Granted Sep 9, 2025·0 cites·16 claims
- 1769US2023159525A1Azetidine and pyrrolidine parp1 inhibitors and uses thereofXINTHERA INC·Filed 2022·Application pending·0 cites
- 1868US2023128041A1Parp1 inhibitors and uses thereofXINTHERA INC·Filed 2022·Application pending·0 cites
- 1967US2021395268A1Chemical compounds as inhibitors of interleukin-1 activityGENENTECH INC·Filed 2021·Application pending·0 cites
- 2065US9481662B2Seriniquinones, melanoma-specific anticancer agentsUNIV CALIFORNIA·Filed 2015·Granted Nov 1, 2016·1 cites·19 claims
- 2164US2025263418A1Modulators of tnf alpha activity and uses thereofRAYTHERA INC·Filed 2025·Application pending·0 cites
- 2262US2025171418A1Parp1 inhibitors and uses thereofXINTHERA INC·Filed 2023·Application pending·0 cites
- 2361US12234245B2Sulfonimidamide compounds as inhibitors of interleukin-1 activityGENENTECH INC·Filed 2021·Granted Feb 25, 2025·0 cites·19 claims
- 2454US11560391B2Sulfonylurea compounds as inhibitors of interleukin-1 activityGENENTECH INC·Filed 2021·Granted Jan 24, 2023·0 cites·21 claims
- 2550US2024148732A1Tricyclic compounds useful in the treatment of cancer, autoimmune and inflammatory disordersSCHROEDINGER INC·Filed 2022·Application pending·0 cites
- 2646US2024018157A1Cyclic compounds and methods of using sameSCHROEDINGER INC·Filed 2020·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Lynnie Trzoss files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →